<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03234348</url>
  </required_header>
  <id_info>
    <org_study_id>MAG-01</org_study_id>
    <nct_id>NCT03234348</nct_id>
  </id_info>
  <brief_title>MAGnesium-based Bioresorbable Scaffold in ST Segment Elevation Myocardial Infarction</brief_title>
  <acronym>MAGSTEMI</acronym>
  <official_title>MAGnesium-based Bioresorbable Scaffold and Vasomotor Function in Patients With Acute ST Segment Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish Society of Cardiology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, active control, single-blind, non-inferiority, multicenter
      clinical trial. 148 subjects will be registered at up to 10 Spanish sites. Subjects will be
      followed for 5 years.

      All eligible patients (STEMI &lt; 12 hours from onset of chest pain) will be randomized to

        -  Biotronik MAGMARISTM Sirolimus Eluting Bioresorbable Vascular Scaffold System (M-BRS) or

        -  Biotronik ORSIRO Sirolimus Eluting Coronary Stent System

      Endothelium-independent vasomotor response (NTG injection) will be analyzed at 12 months
      angiographic follow-up (Primary endpoint).

      In a subgroup of 40 patients Optical Coherence Tomography will be performed after the
      procedure and at 12 months follow-up.

      Angiographic (QCA pre- and post-procedure and at 12 months follow-up), OCT data (at 12 months
      follow-up) will be analyzed off-line by an independent core lab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomised to one of two groups:
MAGMARIS stent arm or ORSIRO stent arm in the ratio of 1:1</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Neither the participant ot the outcomes assessor will be aware of the treatment received. The patient will be blinded until the primary endpoint is reached (1 year follow-up).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent/scaffold vasodilatory endothelium independent response</measure>
    <time_frame>12 months follow-up</time_frame>
    <description>in-stent/scaffold vasodilatory response ≥3% (delta in mean lumen diameter) after nitroglycerin injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>Immediate after the procedure</time_frame>
    <description>implantation of the intended device with attainment of &lt;30% residual stenosis of the target lesion and TIMI ≥2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure success</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>device success and no in-hospital cardiac events: death, repeat MI, TVR or stent/scaffold thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device-oriented Composite Endpoint (DOCE)</measure>
    <time_frame>1, 6 months, 1,2,3,4,5 years</time_frame>
    <description>Combined of cardiac death, Target vessel MI, or clinically-indicated target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>1, 6 months, 1,2,3,4,5 years</time_frame>
    <description>ARC definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel MI</measure>
    <time_frame>1, 6 months, 1,2,3,4,5 years</time_frame>
    <description>ARC definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically driven target lesion revascularization</measure>
    <time_frame>1, 6 months, 1,2,3,4,5 years</time_frame>
    <description>ARC definition-Ischemia driven revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent/scaffold thrombosis</measure>
    <time_frame>1, 6 months, 1,2,3,4,5 years</time_frame>
    <description>ARC definition: definite, probable, possible, acute, subacute, late and very late</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient oriented endpoint (POCE)</measure>
    <time_frame>1, 6 months, 1,2,3,4,5 years</time_frame>
    <description>Combined of all-cause death, any repeat myocardial infarction and any revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>1, 6 months, 1,2,3,4,5 years</time_frame>
    <description>All-cause death rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any repeat myocardial infarction</measure>
    <time_frame>1, 6 months, 1,2,3,4,5 years</time_frame>
    <description>According to WHO extended definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any revascularization</measure>
    <time_frame>1, 6 months, 1,2,3,4,5 years</time_frame>
    <description>Any repeat intervention in the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>1, 6 months, 1,2,3,4,5 years</time_frame>
    <description>ARC definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>1, 6 months, 1,2,3,4,5 years</time_frame>
    <description>ARC definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MLD</measure>
    <time_frame>Baseline and 1 year follow-up</time_frame>
    <description>Minimal lumen diameter by QCA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%DS</measure>
    <time_frame>Baseline and 1 year follow-up</time_frame>
    <description>percentage diameter stenosis by QCA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute gain</measure>
    <time_frame>Baseline</time_frame>
    <description>MLD post - MLD pre by QCA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late loss</measure>
    <time_frame>1 year</time_frame>
    <description>MLD post - MLD at 1 year follow-up by QCA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis</measure>
    <time_frame>1 year</time_frame>
    <description>% of patients with &gt;50% DS at 1 year follow-up by QCA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lumen area</measure>
    <time_frame>1 year follow-up</time_frame>
    <description>Mean and minimum lumen area of the stented/scaffolded segment by OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean lumen volume</measure>
    <time_frame>1 year follow-up</time_frame>
    <description>mean lumen volume of the stented/scaffolded segment by OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% strut malapposition</measure>
    <time_frame>1 year follow-up</time_frame>
    <description>mean area of strut malapposition by OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue Prolapse</measure>
    <time_frame>1 year follow-up</time_frame>
    <description>presence and % of lumen area occupied by tissue prolapse by OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neointimal hyperplasia</measure>
    <time_frame>1 year follow-up</time_frame>
    <description>mean intra-stent/scaffold area occupied by neointimal hyperplasia by OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healing index</measure>
    <time_frame>1 year follow-up</time_frame>
    <description>Index obtained by a combination of % malapposition, % coverage, % tissue prolapse by OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Strut coverage</measure>
    <time_frame>1 year follow-up</time_frame>
    <description>Presence and amount of tissue covering the strut of the stent/scaffold by OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RUTTS</measure>
    <time_frame>1 year follow-up</time_frame>
    <description>Ratio of Uncovered to Total Stent/scaffold Struts Per Cross Section (RUTTS) score of ≤30% of the target stent/scaffold as determined by OCT pullback</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>ST Segment Elevation Myocardial Infarction</condition>
  <condition>Stent</condition>
  <arm_group>
    <arm_group_label>Magmaris</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous coronary intervention by means of Magnesium-based sirolimus-eluting bioresorbable scaffold implantation after proper lesion preparation by balloon predilatation and/or manual thrombectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orsiro</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Percutaneous coronary intervention by means of Biodegradable polymer sirolimus-eluting stent implantation after proper lesion preparation by balloon predilatation and/or manual thrombectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous coronary intervention</intervention_name>
    <description>PCI + stent implantation</description>
    <arm_group_label>Magmaris</arm_group_label>
    <arm_group_label>Orsiro</arm_group_label>
    <other_name>stent implantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Clinical:

          1. At least 18 years of age.

          2. ST-segment elevation Myocardial Infarction documented in an ambulance or in a Cathlab,
             with ≥2 mm ST segment elevation in at least two contiguous leads, presenting in the
             Cathlab &lt;12 hours after the onset of symptoms lasting ≥20 min requiring primary PCI.

          3. Target lesion must be a de-novo lesion located in a native vessel.

          4. The patient accepts Informed Consent

          5. The patient understands and accepts clinical follow-up and angiographic control.

             Angiographic:

          6. Vessel size should match available M-BRS scaffold sizes (≥2.75 mm, and ≤3.7 mm by
             visual assessment).

          7. Lesion preparation by either manual thrombectomy or pre-dilatation has been
             successful, with opening of the vessel and TIMI ≥2 and residual stenosis &lt;20%.

        Exclusion Criteria:

          1. Pregnancy.

          2. Known intolerance to aspirin, heparin, stainless steel, sirolimus, and contrast
             material.

          3. Distal vessel occlusion after recanalization

          4. STEMI due to stent/scaffold thrombosis

          5. Severe tortuous, calcified or angulated coronary anatomy of the study vessel that in
             the opinion of the investigator would result in sub-optimal m-BRS placement.

          6. Fibrinolysis prior to PCI

          7. Known thrombocytopenia (PLT&lt; 100,000/mm3)

          8. Active bleeding or coagulopathy or patients at chronic anticoagulation therapy

          9. Cardiogenic Shock

         10. Significant comorbidities precluding clinical/angiographic FU (as judged by
             investigators)

         11. Major planned surgery that requires discontinuation of dual antiplatelet therapy.

         12. Diffuse coronary artery disease that will require CABG

         13. Chronic kidney disease with GFR&lt;30 ml/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manel Sabaté, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gema Céspedes</last_name>
    <phone>(+34) 91 724 23 70</phone>
    <phone_ext>2018</phone_ext>
    <email>gcespedes@secardiologia.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manel Sabaté, MD</last_name>
    <phone>+34932279305</phone>
    <email>masabate@clinic.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clínic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manel Sabate, MD</last_name>
      <phone>+34932279305</phone>
      <email>masabate@clinic.cat</email>
    </contact>
    <contact_backup>
      <last_name>Salvatore Brugaletta, MD</last_name>
      <phone>+34932279305</phone>
      <email>sabrugal@clinic.cat</email>
    </contact_backup>
    <investigator>
      <last_name>Xavier Freixa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Salvatore Brugaletta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victoria Martín-Yuste, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ander Regueiro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mónica Masotti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manel Sabaté, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Cequier</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro Majadahonda</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Alvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2017</study_first_submitted>
  <study_first_submitted_qc>July 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2017</study_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Manel Sabate</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>biodegradable stent</keyword>
  <keyword>STEMI</keyword>
  <keyword>Magnesium bioresorbable</keyword>
  <keyword>Vasomotion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data on primary/secondary outcomes on individual basis may be shared with other researchers once main report as been published and review and approval of the research proposal by the steering committee of the Magstemi Trial</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

